In Supplementary Figure S2, the representative cases were shown: the 90-day outcomes were poor when the plasma FBLN5 levels at days 4–6 post-SAH were ≥487.2 ng/mL, and good (mRS 0–2), when those were <487.2 ng/mL, regardless of the admission WFNS grades, the modified Fisher grades, and the presence or absence of a delayed cerebral infarction. This evidence concerns the gene FBLN5 and brain infarction.